Shaowei Bo

Shaowei Bo

Auto-generated profile, based on publicly available information

Shaowei Bo

Department of Nuclear Medicine The Affiliated Guangdong Second Provincial General Hospital of Jinan University Guangzhou Guangdong China

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 October 2015 in Journal of Applied Biopharmaceutics and Pharmacokinetics
Verified
Journal Article
Closed access
XZXing Zheng
Xing Zheng
QZQutong Zheng
Qutong Zheng
SBShaowei Bo
Shaowei Bo
XZXianliang Zeng
Xianliang Zeng
YWYun Wei
Yun Wei
ZWZongbao Wang
Zongbao Wang

11 November 2024 in Magnetic Resonance in Medicine
Verified
Journal Article
Closed access
CBChongxue Bie
Chongxue Bie
SBShaowei Bo
Shaowei Bo
NYNirbhay N. Yadav
Nirbhay N. Yadav
PZPeter C. M. van Zijl
Peter C. M. van Zijl
TWTao Wang
Tao Wang
YZYang Zhou
Yang Zhou

23 April 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
SBShaowei Bo
Shaowei Bo
DZDong Zhang
Dong Zhang
MMMengjie Ma
Mengjie Ma
XMXukai Mo
Xukai Mo
JSJulia Stabinska
Julia Stabinska
JLJianping Luo
Jianping Luo
Chemical exchange saturation transfer (CEST) MRI is a versatile molecular imaging approach that holds great promise for clinical translation. A number of compounds have been identified as suitable for performing CEST MRI, including paramagnetic CEST (paraCEST) agents and diamagnetic CEST (diaCEST) agents. DiaCEST agents are very attractive because of their excellent biocompatibility and potential for biodegradation, such as glucose, glycogen, glutamate, creatine, nucleic acids, et al. However, the sensitivity of most diaCEST agents is limited because of small chemical shifts (1.0–4.0 ppm) from water. To expand the catalog of diaCEST agents with larger chemical shifts, herein, we have systematically investigated the CEST properties of acyl hydrazides with different substitutions, including aromatic and aliphatic substituents. We have tuned the labile proton chemical shifts from 2.8–5.0 ppm from water while exchange rates varied from ~680 to 2340 s−1 at pH 7.2, which allows strong CEST contrast on scanners down to B0 = 3 T. One acyl hydrazide, adipic acid dihydrazide (ADH), was tested on a mouse model of breast cancer and showed nice contrast in the tumor region. We also prepared a derivative, acyl hydrazone, which showed the furthest shifted labile proton (6.4 ppm from water) and excellent contrast properties. Overall, our study expands the catalog of diaCEST agents and their application in cancer diagnosis.

22 July 2026 in Advanced Functional Materials
Verified
Journal Article
Open access
PDF file
ZYZian Yu
Zian Yu
SBShaowei Bo
Shaowei Bo
JLJiangli Li
Jiangli Li
QYQin Yu
Qin Yu
YHYifan Huang
Yifan Huang
YYYue Yuan
Yue Yuan
Triple‐negative breast cancer (TNBC) is an aggressive subtype of breast cancer lacking specific molecular targets, hindering effective therapy and real‐time efficacy monitoring. Here, we present an innovative, streamlined self‐reporting nanoprobe, NapYpSA, addressing these challenges without additional probe labeling. NapYpSA nanospheres first undergo alkaline phosphatase (ALP)‐induced internalization and dephosphorylation, improving cellular uptake and promoting the transition to dense NapYSA nanofibers in ALP‐overexpressing TNBC cells. Subsequently, esterase hydrolysis slowly releases salicylic acid (SA), which inhibits COX‐2 and activates a chemical exchange saturation transfer (CEST) MRI signal, further transforming the NapYSA nanofibers into sparse NapY nanofibers for post‐apoptotic clearance. By combining in situ nanofiber transformation‐induced disruption of microtubule polymerization with enhanced COX‐2 inhibition mediated by SA accumulation, this cascade enzymatic cleavage‐triggered nanostructure transition not only improves tumor treatment efficacy but also reduces toxic side effects. Moreover, the increased local SA concentration also amplifies the CEST signal, enabling real‐time tracking of drug activation with a clinical 3.0 T MRI scanner. In vivo studies demonstrated that ALP activity, CEST signal intensity, and antitumor efficacy were closely linked. Therefore, this self‐reporting strategy not only enhances TNBC therapy but also enables CEST MRI‐guided identification of highly responsive tumors at treatment initiation, thereby facilitating precise therapeutic intervention.